CA2164848A1 - Interleukin-2 stimulated t lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejection - Google Patents
Interleukin-2 stimulated t lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejectionInfo
- Publication number
- CA2164848A1 CA2164848A1 CA002164848A CA2164848A CA2164848A1 CA 2164848 A1 CA2164848 A1 CA 2164848A1 CA 002164848 A CA002164848 A CA 002164848A CA 2164848 A CA2164848 A CA 2164848A CA 2164848 A1 CA2164848 A1 CA 2164848A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- cells
- protein
- immunization
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of autoimmune diseases such as, for example, multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, autoimmune myocardis, allergic disorders such as hay fever, extrinsic asthma, or insect bite and sting allergies. food and drug allergies, as well as for the treatment or prevention of graft rejection.
Claims (24)
1. A method for treating or preventing a disease in a human or animal caused by antigen-activated T cells, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing said disease to an extent greater than that of other T lymphocytes.
2. The method of claim 1, wherein said apoptosis is achieved by a cycle comprising challenging via immunization said T cells with a substance selected from the group consisting of an antigen, a peptide, a protein, a polysaccharide, an organic molecule, and a nucleic acid, followed by increasing the amount of IL-2 in said human or animal when said T cells are expressing high levels of IL-2 receptor, so as to cause said T cells to undergo apoptosis upon re-immunization with said substance.
3. The method of claim 2, wherein said antigen, peptide, or protein is selected from the group consisting of one leading to an autoimmune disease, an allergic or atopic disorder, and graft rejection.
4. The method of claim 3, wherein said autoimmune disease is selected from the group consisting of multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, and autoimmune myocarditis.
5. The method of claim 3, wherein said allergic disorder is selected from the group consisting of hay fever, extrinsic asthma, insect bite and sting allergies, and food or drug allergies.
6. The method of claim 2, wherein said challenging via immunization is conducted by administering said antigenic peptide or protein at a dose effective to cause said T cells to express high affinity IL-2 receptors and/or to produce and secrete IL-2.
7. The method of claim 2, wherein said challenging via immunization is conducted by administering said antigenic peptide or protein at a dose between about 10 to about 1000 µg.
8. The method of claim 2, wherein said challenging via immunization is conducted by administering said antigenic peptide or protein orally or intramuscularly.
9. The method of claim 3, wherein said antigenic peptide or protein is selected from the group consisting of myelin basic protein residue 84-102, myelin basic protein residue 143-168, human S antigen, type II collagen, thyroglobulin, Amb a V, Amb t V, an antigen inciting hay fever, an antigen derived from insect venom, an antigen derived from insect saliva, a food antigen, a drug antigen, and a donor class I major histocom-patibility complex antigen.
10. The method of claim 9, wherein said antigen derived from insect venom is antigen V of hornet venom.
11. The method of claim 9, wherein said food antigen is codfish allergen M.
12. The method of claim 2, wherein said challenging Via immunization is followed by a period of time between about 12 to about 72 hours before administering an additional high dose of IL-2.
13. The method of claim 2, wherein a high dose of IL-2 is administered intravenously, either as a continuous infusion or as frequent bolus doses.
14. The method of claim 2, wherein a high dose of IL-2 is in the range between about 300 to about 3,000 units/kg/hour continuous infusion, or from about 104 to about 106 units/kg intravenous bolus.
15. The method of claim 13, wherein said continuous infusion is conducted for a period of time between about 48 to about 72 hours.
16. The method of claim 2, wherein said cycle is repeated up to an endpoint selected from the group consisting of elimination of in vitro reactivity to said antigenic peptide or protein, amelioration of clinical symptoms, decreased allergic skin test, reduction in serum IgE, and toxicity.
17. The method of claim 9, wherein said donor class I major histocompatibility complex antigen is administered in the form of whole blood, packed cell equivalent, or a washed packed cell transfusion.
18. The method of claim 17, wherein said whole blood is administered in a dose of about 50 to about 200 ml.
19. The method of claim 18, wherein the total amount of whole blood administered is determined by the fluid tolerance of end-stage renal disease in the recipient.
20. The method of claim 19, wherein said cycle is repeated up to an endpoint selected from the group consisting of a diminished requirement for general immunosuppressive medications, graft survival, and adequate function of said graft.
21. The method of claim 2, wherein said cycle comprises challenging via immunization said T cells by repeated administration of said substance without the subsequent exogenous administration of IL-2.
22. The method of claim 21, wherein said cycle of repeated administration is performed at a short time interval.
23. The method of claim 22, wherein said time interval is in the range of from about one to about five days.
24. The method of claim 22, wherein said time interval is in the range of from about one to about three days.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1993/005481 WO1994028926A1 (en) | 1993-06-09 | 1993-06-09 | Interleukin-2 stimulated t lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2164848A1 true CA2164848A1 (en) | 1994-12-22 |
| CA2164848C CA2164848C (en) | 2010-08-03 |
Family
ID=22236680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2164848A Expired - Lifetime CA2164848C (en) | 1993-06-09 | 1993-06-09 | Interleukin-2 stimulated t lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejection |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0705107A4 (en) |
| AU (1) | AU699217B2 (en) |
| CA (1) | CA2164848C (en) |
| WO (1) | WO1994028926A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113684179A (en) * | 2021-08-27 | 2021-11-23 | 广州百暨基因科技有限公司 | Cell amplification medium for gamma delta T, combination product and culture method thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041503B2 (en) | 1995-05-02 | 2006-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Modified myelin basic protein molecules |
| RU2126971C1 (en) * | 1996-04-29 | 1999-02-27 | Московский научно-исследовательский институт глазных болезней им.Гельмгольца | Method of diagnosis of enterovirus uveitis in children in remote terms |
| RU2148260C1 (en) * | 1998-10-12 | 2000-04-27 | Слепова Ольга Семеновна | Method for predicting risk of second eye falling ill in the cases of endogenous uveitis |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4904481A (en) * | 1985-04-17 | 1990-02-27 | The Board Of Trustess Of Leland Stanford University | Method of conferring immuno-tolerance to a specific antigen |
| WO1994003202A1 (en) * | 1992-08-10 | 1994-02-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Interleukin-4 stimulated t lymphocyte cell death |
-
1993
- 1993-06-09 EP EP93916463A patent/EP0705107A4/en not_active Ceased
- 1993-06-09 WO PCT/US1993/005481 patent/WO1994028926A1/en not_active Ceased
- 1993-06-09 AU AU46305/93A patent/AU699217B2/en not_active Expired
- 1993-06-09 CA CA2164848A patent/CA2164848C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113684179A (en) * | 2021-08-27 | 2021-11-23 | 广州百暨基因科技有限公司 | Cell amplification medium for gamma delta T, combination product and culture method thereof |
| CN113684179B (en) * | 2021-08-27 | 2022-06-10 | 广州百暨基因科技有限公司 | Cell amplification medium for gamma delta T, combination product and culture method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU699217B2 (en) | 1998-11-26 |
| EP0705107A1 (en) | 1996-04-10 |
| AU4630593A (en) | 1995-01-03 |
| EP0705107A4 (en) | 1997-11-19 |
| WO1994028926A1 (en) | 1994-12-22 |
| CA2164848C (en) | 2010-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100294060B1 (en) | Use of hyaluronic acid as an immunosuppressant | |
| Engelhardt et al. | Biological response to intravenously administered endotoxin in patients with advanced cancer | |
| KAUFMAN et al. | L-Tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis: a clinicopathologic and laboratory study of 25 patients | |
| Kastin et al. | Extrapigmentary effects of melanocyte-stimulating hormone in amenorrhoeic women | |
| Shiba et al. | Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis | |
| US5624938A (en) | Use of chloroquine to treat multiple sclerosis | |
| US6083503A (en) | Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection | |
| EP0655927B1 (en) | Interleukin-4 stimulated t lymphocyte cell death | |
| CA2164848A1 (en) | Interleukin-2 stimulated t lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejection | |
| Brod et al. | Ingested interferon α suppresses type I diabetes in non-obese diabetic mice | |
| EP0609701A1 (en) | L-cystein, L-cystine or L-glutamine as a supplementary therapeutic agent for the treatment of immunodeficiency syndrome | |
| US6809084B1 (en) | Compositions containing polysaccharides from phellinus linteus and methods for treating diabetes mellitus using same | |
| US6713053B1 (en) | Use of IL-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular | |
| AU688490B2 (en) | Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection | |
| Bird et al. | Prolonged hypoglycemia secondary to tolbutamide | |
| Verda et al. | Effect of hematopoietic growth factors on severity of experimental autoimmune encephalomyelitis | |
| Saheki et al. | Co-existing of neuromyelitis optica and fulminant type 1 diabetes | |
| SIMPSON et al. | Fatal aplastic anemia occurring during anticonvulsant therapy: probable idiosyncrasy to phenurone | |
| Callera et al. | Evaluation of cytokine profile in the different phases of the autologous hematopoietic stem cell transplantation in patients with multiple myeloma | |
| Bachmann et al. | Efficiency of human insulin (recombinant DNA) in the treatment of diabetic ketoacidosis and severe nonketoacidotic hyperglycemia | |
| RU2365381C2 (en) | Method of chronic virus hepatitis b treatment | |
| Beech et al. | Phenytoin toxicity produced by tolbutamide | |
| CN102793690A (en) | Application of juglone to preparation of medicament for treating autoimmune and inflammatory diseases | |
| RU2157237C2 (en) | Method of hyperglycaemia correction | |
| Rich et al. | Principles of Immune |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |